Akers Biosciences Inc.

2.47-0.2600-9.52%Vol 1.58M1Y Perf -32.69%
Apr 16th, 2021 16:00 DELAYED
BID2.40 ASK2.53
Open2.65 Previous Close2.73
Pre-Market- After-Market2.43
 - -  -0.04 -1.62%
Target Price
- 
Analyst Rating
— 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     66.01
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap41.13M 
Earnings Rating
Buy
Price Range Ratio 52W %
15.41 
Earnings Date
21st May 2021

Today's Price Range

2.403.04

52W Range

1.656.97

5 Year PE Ratio Range

-0.6000-1.20

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-23.05%
1 Month
-32.88%
3 Months
-6.79%
6 Months
8.81%
1 Year
-32.69%
3 Years
-97.60%
5 Years
-99.23%
10 Years
-

TickerPriceChg.Chg.%
AKER2.47-0.2600-9.52
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
16.10
16.30
0.02
0.00
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
30.40
-649.20
-646.20
-280.80
-
RevenueValueIndustryS&P 500US Markets
-363 515.00
-0.02
-49.94
-29.21
Earnings HistoryEstimateReportedSurprise %
Q03 2020--0.38-
Q01 2020--1.59-
Q03 2019--0.07-
Q02 2019--0.06-
Q01 2019--0.07-
Q04 2018--0.34-
Q03 2018--0.26-
Q02 2018--0.02-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date21st May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.58M
Shares Outstanding16.65M
Trades Count7.89K
Dollar Volume1.18M
Avg. Volume770.29K
Avg. Weekly Volume697.67K
Avg. Monthly Volume347.60K
Avg. Quarterly Volume810.80K

Akers Biosciences Inc. (NASDAQ: AKER) stock closed at 2.47 per share at the end of the most recent trading day (a -9.52% change compared to the prior day closing price) with a volume of 1.58M shares and market capitalization of 41.13M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 12 people. Akers Biosciences Inc. CEO is Christopher Charles Schreiber.

The one-year performance of Akers Biosciences Inc. stock is -32.69%, while year-to-date (YTD) performance is 24.12%. AKER stock has a five-year performance of -99.23%. Its 52-week range is between 1.65 and 6.97, which gives AKER stock a 52-week price range ratio of 15.41%

Akers Biosciences Inc. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 1.61, a price-to-sale (PS) ratio of -159.88, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -72.21%, a ROC of -127.53% and a ROE of -78.80%. The company’s profit margin is -%, its EBITDA margin is -646.20%, and its revenue ttm is $-363 515.00 , which makes it $-0.02 revenue per share.

Of the last four earnings reports from Akers Biosciences Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Akers Biosciences Inc.’s next earnings report date is 21st May 2021.

The consensus rating of Wall Street analysts for Akers Biosciences Inc. is (0), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Akers Biosciences Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Akers Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Akers Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.48, ATR14 : 0.44, CCI20 : -197.90, Chaikin Money Flow : -0.46, MACD : -0.11, Money Flow Index : 28.18, ROC : -19.28, RSI : 40.56, STOCH (14,3) : 5.83, STOCH RSI : 0.00, UO : 31.81, Williams %R : -94.17), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Akers Biosciences Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Strong Buy
1.00

Akers Biosciences Inc.

Akers Biosciences Inc is engaged in developing, manufacturing and supplying rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner. The pipeline products of the company focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious disease detection. The majority of the company's revenue comes from the United States.

CEO: Christopher Charles Schreiber

Telephone: +1 856 848-8698

Address: 201 Grove Road, Thorofare 08086, NJ, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

67%33%

Bearish Bullish

68%32%

Bearish Bullish

72%28%

News

Stocktwits